Publications by authors named "Scott Furness"

Claim this Profile
A
Analysis of Regulatory Botanical Submission Profile for Cancer Management from the U.S. FDA Perspectives.
Jin-Young K Park, Daniel Lee, Lixin Rui, Xiaoyue Gao, M Scott Furness

Ther Innov Regul Sci· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling Approaches to Reimagine Stability (MARS) for Enabling Earlier Access to Critical Drugs for Patients with Unmet Medical Needs.
M Scott Furness, Hong Cai, Sithamalli Chandramouli, Mariappan Chelliah, Xiao Hong Chen

AAPS PharmSciTech· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methionine AminoPeptidase Type-2 Inhibitors Targeting Angiogenesis.
Tedman Ehlers, Scott Furness, Thomas Philip Robinson, Haizhen A Zhong, David Goldsmith

Curr Top Med Chem· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing Product Quality: a Summary of the Second FDA/PQRI Conference.
Lawrence X Yu, Ilgaz Akseli, Barbara Allen, Gregory Amidon, Tara Gooen Bizjak, Scott Furness

AAPS J· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dissolution Testing for Bioavailability of Over-the-Counter (OTC) Drugs--a Technical Note.
Zongming Gao, Lawrence Yu, Stephanie Clark, Mike Trehy, Terry Moore, Scott Furness

AAPS PharmSciTech· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 2: Safety considerations of impurities in pharmaceutical products and surveying the impurity landscape.
Karen M Alsante, Kim C Huynh-Ba, Steven W Baertschi, Robert A Reed, Margaret S Landis, Scott Furness

AAPS PharmSciTech· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory review of acetaminophen clinical pharmacology in young pediatric patients.
Ping Ji, Yaning Wang, Zhihong Li, Suresh Doddapaneni, Sharon Hertz, Scott Furness

J Pharm Sci· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis.
Jack L Arbiser, Tweeny Kau, Martha Konar, Krishna Narra, Ramani Ramchandran, Scott Furness

Blood· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications.
Arup K Basak, Andre S Raw, Ali H Al Hakim, Scott Furness, Nashed I Samaan

Adv Drug Deliv Rev· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).
Andre S Raw, M Scott Furness, Devinder S Gill, Richard C Adams, Frank O Holcombe

Adv Drug Deliv Rev· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diaryldimethylpiperazine ligands with mu- and delta-opioid receptor affinity: Synthesis of (+)-4-[(alphaR)-alpha-(4-allyl-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-phenylbenzamide and (-)-4-[(alphaR)-alpha-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-phenylbenzamide.
In Jong Kim, Thomas Ullrich, James W Janetka, M Scott Furness, Arthur E Jacobson

Bioorg Med Chem· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enantioconvergent synthesis of (-)-(2R,5S)-1-allyl-2,5-dimethylpiperazine, an intermediate to delta-opioid receptor ligands.
James W Janetka, M Scott Furness, Xiaoyan Zhang, Andrew Coop, John E Folk

J Org Chem· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scientific considerations of pharmaceutical solid polymorphism in abbreviated new drug applications.
Lawrence X Yu, M Scott Furness, Andre Raw, Kathy P Woodland Outlaw, Nashed E Nashed

Pharm Res· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis